|
|
|
|
|
|
|
|
The ASCO Post
Key Points
- Worsening of menopause-specific quality of life was associated with early discontinuation of chemopreventive therapy with aromatase inhibitors.
- Worsening in vasomotor, sexual, physical, and psychosocial domains were each associated with early treatment discontinuation.
Study Details
In the MAP.3 trial, 4,560 high-risk postmenopausal women were randomized between 2004 and 2010 to receive exemestane at 25 mg or placebo for 5 years. The current analysis included 4,501 participants, who completed the Menopause-Specific Quality-of-Life Questionnaire (MENQOL) at study entry and at 6 months.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.